Fresh analysis indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise plans.
Research printed in a major medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying such treatments should be cognizant of the potential of rapid rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a return to original mass within about 18 months.
Weighing Treatments
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the effects of these new drugs with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone usually have a slower creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Nutrition scientists propose the mechanism of the injections explains the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means hunger is unsuppressed, making excessive eating much more probable."
A Lifelong Disease?
The NHS recommend the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, given the high risk of relapse, the therapy should be considered life-long.
This view is supported by pharmaceutical companies, who state that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the medication report a sudden resurgence of hunger.
"I experienced something that goes on and you're instantly ravenous," described an individual.
This challenge is exacerbated if users have not developed sustainable lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates indicate that millions of people in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss relies on ongoing behavioural changes.
